# Weight Loss Surgeries Decline as GLP-1 Use Skyrockets. Why This Matters
Bariatric surgery numbers are dropping sharply as families turn to GLP-1 medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) to manage weight. This shift marks a fundamental change in how parents and teens approach obesity treatment.
GLP-1 drugs work by regulating appetite and blood sugar. They've become easier to access and carry lower upfront risks than surgery, which explains their rapid adoption. Families appreciate avoiding the recovery time, expense, and permanent digestive changes that bariatric procedures require. Insurance coverage has expanded, making these medications more affordable for many households.
The data tells the story. Bariatric surgery centers report patient volume declines ranging from 20 to 40 percent over the past two years. Simultaneously, prescriptions for GLP-1 medications have exploded, with over 15 million Americans now using them.
For parents considering weight management options for their children, this shift offers real advantages. GLP-1 medications are reversible. If your child experiences side effects like nausea or loses too much weight, you can stop the medication. Surgery, by contrast, permanently alters the digestive system. The FDA approved tirzepatide for adolescents ages 12 and up in 2023, opening new treatment pathways.
However, GLP-1 drugs aren't perfect solutions. Long-term safety data in children remains limited. Some teens experience persistent gastrointestinal issues or muscle loss. The medications also require ongoing use. Stop taking them, and weight often returns. Cost varies dramatically by insurance plan, and some families face significant out-of-pocket expenses.
Bariatric surgery still